Literature DB >> 18348300

Indicators of survival duration in ovarian cancer and implications for aggressiveness of care.

Vivian von Gruenigen1, Barbara Daly, Heidi Gibbons, Jessica Hutchins, Andrew Green.   

Abstract

BACKGROUND: Ovarian cancer patients frequently receive chemotherapy near the end of life. The purpose of the current study was to develop indicators that characterize those ovarian cancer patients who have a short life span.
METHODS: The medical charts of deceased epithelial ovarian cancer patients were retrospectively reviewed from 2000 through 2006. All patients received primary debulking surgery and adjuvant chemotherapy. Aggressiveness of cancer care within the last month of life was measured by chemotherapy regimens, emergency room visits, and hospitalizations. Significant clinical events (SCE) were defined as ascites, bowel obstruction, and pleural effusion. Survival quartiles were compared using chi-square and Student t test statistics. Multiple regression analysis was performed using survival duration as a dependent variable.
RESULTS: In all, 113 patients with epithelial ovarian cancer were reviewed. Patients had increased hospitalizations (P < .001) and SCE (P < .001) as they approached the end of life. There was no difference in the pattern of hospitalizations and SCE between the top and bottom survival quartiles. Patients with a shorter survival time had a trend toward increased chemotherapy during their last 3 months of life (P = .057) and had increased overall aggressiveness of care (P = .013). In patients with a disease remission, the length of initial remission time was found to be significant in predicting survival (P < .01). Time to second disease recurrence was also significant in predicting survival time (P < 0.01).
CONCLUSIONS: Patients who received aggressive care did not have improvement in survival. Short disease remissions and increasing hospitalizations with SCE should be indicators of the appropriateness of reducing cure-oriented therapies and increasing palliative interventions. (c)2008 American Cancer Society.

Entities:  

Mesh:

Year:  2008        PMID: 18348300     DOI: 10.1002/cncr.23391

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Advancing performance measurement in oncology: quality oncology practice initiative participation and quality outcomes.

Authors:  Francis X Campion; Leanne R Larson; Pamela J Kadlubek; Craig C Earle; Michael N Neuss
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

2.  Processes of discontinuing chemotherapy for metastatic non-small-cell lung cancer at the end of life.

Authors:  William F Pirl; Joseph A Greer; Kelly Irwin; Inga T Lennes; Vicki A Jackson; Elyse R Park; Daisuke Fujisawa; Alexi A Wright; Jennifer S Temel
Journal:  J Oncol Pract       Date:  2015-03-31       Impact factor: 3.840

Review 3.  The impact of specialized palliative care on cancer patients' health-related quality of life: a systematic review and meta-analysis.

Authors:  Angelos P Kassianos; Myria Ioannou; Marianna Koutsantoni; Haris Charalambous
Journal:  Support Care Cancer       Date:  2017-09-20       Impact factor: 3.603

4.  Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.

Authors:  Peter G Rose; James J Java; Ritu Salani; Melissa A Geller; Angeles Alvarez Secord; Krishnansu S Tewari; David P Bender; David G Mutch; Michael L Friedlander; Linda Van Le; Michael W Method; Chad A Hamilton; Roger B Lee; Robert M Wenham; Saketh R Guntupalli; Maurie Markman; Franco M Muggia; Deborah K Armstrong; Michael A Bookman; Robert A Burger; Larry J Copeland
Journal:  Obstet Gynecol       Date:  2019-02       Impact factor: 7.661

5.  End-of-life care of women with gynecologic malignancies: a pilot study.

Authors:  Nicole S Nevadunsky; Lori Spoozak; Sharon Gordon; Enid Rivera; Kimala Harris; Gary L Goldberg
Journal:  Int J Gynecol Cancer       Date:  2013-03       Impact factor: 3.437

6.  Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Vivian E von Gruenigen; Helen Q Huang; David Cella; MichaelA Zevon; Jason A LaChance; Joan L Walker; Ritu Salani; Susan C Modesitt; Robert T Morris; William H Bradley; Matthew P Boente; Lari Wenzel
Journal:  Gynecol Oncol       Date:  2018-05-18       Impact factor: 5.482

7.  End-of-life care for older patients with ovarian cancer is intensive despite high rates of hospice use.

Authors:  Alexi A Wright; Laura A Hatfield; Craig C Earle; Nancy L Keating
Journal:  J Clin Oncol       Date:  2014-10-06       Impact factor: 44.544

8.  Dying well: How equal is end of life care among gynecologic oncology patients?

Authors:  Jolyn S Taylor; Alaina J Brown; Lauren S Prescott; Charlotte C Sun; Lois M Ramondetta; Diane C Bodurka
Journal:  Gynecol Oncol       Date:  2015-12-17       Impact factor: 5.482

9.  Missed opportunities: Patterns of medical care and hospice utilization among ovarian cancer patients.

Authors:  Alaina J Brown; Charlotte C Sun; Lauren S Prescott; Jolyn S Taylor; Lois M Ramondetta; Diane C Bodurka
Journal:  Gynecol Oncol       Date:  2014-09-02       Impact factor: 5.482

10.  The role and timing of palliative medicine consultation for women with gynecologic malignancies: association with end of life interventions and direct hospital costs.

Authors:  Nicole S Nevadunsky; Sharon Gordon; Lori Spoozak; Anne Van Arsdale; Yijuan Hou; Merieme Klobocista; Serife Eti; Bruce Rapkin; Gary L Goldberg
Journal:  Gynecol Oncol       Date:  2013-10-29       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.